Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for Lu-177-PSMA and Lu-177-DOTATATE) into all patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed qualities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are difficult to control. A fixed administered dosage results in the undertreatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players.
The South & Central America radiopharmaceutical theranostics market is segmented into the Argentina, Brazil, and the rest of South & Central America. The market growth in this region is due to the increasing prevalence of cancer and cardiovascular diseases, and presence of supportive government plans. Growing diabetes who are prone to cardiovascular disease is promoting the growth of radiopharmaceutical theranostics market in Brazil. Further, expanding healthcare expenditure in Brazil is boosting the radiopharmaceutical theranostics market.
South & Central America Radiopharmaceutical Theranostics Market Segmentation
The South & Central America radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the South & Central America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.
Based on radioisotype, the South & Central America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the South & Central America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the South & Central America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America radiopharmaceutical theranostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the South & Central America radiopharmaceutical theranostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 129.48 Million |
| Market Size by 2028 | US$ 233.71 Million |
| CAGR (2022 - 2028) | 10.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South & Central America Radiopharmaceutical Theranostics Market is valued at US$ 129.48 Million in 2022, it is projected to reach US$ 233.71 Million by 2028.
As per our report South & Central America Radiopharmaceutical Theranostics Market, the market size is valued at US$ 129.48 Million in 2022, projecting it to reach US$ 233.71 Million by 2028. This translates to a CAGR of approximately 10.3% during the forecast period.
The South & Central America Radiopharmaceutical Theranostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Radiopharmaceutical Theranostics Market report:
The South & Central America Radiopharmaceutical Theranostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Radiopharmaceutical Theranostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Radiopharmaceutical Theranostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Radiopharmaceutical Theranostics Market
